Table 1.9a
Immunosuppression Use by Organ in 2004 and 2005

	Organ								
	Kidney	PTA	PAK	KP	Liver	Intest-ine	Heart	Lung	Heart-Lung
Transplants (2005)	16,477	197	344	903	6,441	176	2,126	1,409	33
Tx With Immunosuppression Info at Discharge	15,820	190	333	887	6,083	164	2,011	1,360	31
Induction Drug Reported	73.6%	83.7%	78.1%	78.1%	20.2%	54.3%	52.2%	42.6%	64.5%
Induction Drugs									
Atgam/NRATG/NRATS	1.6%	0.0%	3.3%	2.4%	0.2%	1.8%	6.8%	3.8%	12.9%
OKT3	0.4%	1.6%	0.0%	0.3%	0.8%	3.7%	3.1%	0.9%	3.2%
Thymoglobulin	38.6%	48.4%	54.4%	51.2%	7.3%	15.2%	14.9%	3.0%	3.2%
Zenapax	11.5%	5.3%	6.9%	4.5%	4.0%	14.0%	15.3%	12.1%	12.9%
Simulect	16.4%	2.1%	2.7%	8.2%	7.1%	3.0%	13.8%	18.3%	25.8%
Campath	8.8%	33.7%	17.7%	14.5%	1.6%	22.6%	0.7%	5.2%	9.7%
Tx With Immunosuppression Info and Functioning Graft at Discharge	15,523	178	299	876	5,718	149	1,903	1,269	27
Maintenance at Discharge									
Corticosteroids Use	73.5%	52.2%	67.2%	71.3%	78.6%	72.5%	93.2%	97.9%	100.0%
Steroids	73.5%	52.2%	67.2%	71.3%	78.6%	72.5%	93.2%	97.9%	100.0%
Calcineurin Inhibitor Use	93.6%	91.6%	92.0%	95.4%	97.7%	96.6%	97.4%	98.3%	103.7%
Cyclosporine	14.9%	0.0%	6.7%	6.7%	6.8%	0.0%	39.4%	22.1%	48.1%
Tacrolimus	78.7%	91.6%	85.3%	88.7%	90.9%	96.6%	58.0%	76.2%	55.6%
Antimetabolite Use	87.5%	58.4%	83.9%	81.6%	61.4%	11.4%	94.1%	91.9%	96.3%
Mycophenolate Mofetil	81.8%	55.6%	79.6%	74.4%	58.5%	11.4%	84.9%	51.4%	55.6%
Mycophenolate Sodium	5.1%	2.8%	3.3%	7.0%	2.1%	0.0%	1.4%	2.1%	0.0%
Azathioprine	0.6%	0.0%	1.0%	0.2%	0.8%	0.0%	7.7%	38.3%	40.7%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%
mTOR Inhibitor Use	9.4%	15.2%	13.7%	15.4%	4.0%	12.1%	4.1%	0.6%	0.0%
Sirolimus	9.1%	15.2%	13.7%	15.4%	4.0%	12.1%	3.7%	0.6%	0.0%
Everolimus	0.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.0%	0.0%
Transplants (2004)	16,004	183	420	881	6,167	152	2,016	1,185	39
Tx With Maintenance Use at 1yr PostTx	13,958	138	317	769	4,861	112	1,709	973	28
Maintenance at 1yr PostTx									
Corticosteroids Use	75.5%	47.8%	70.0%	71.4%	43.6%	63.4%	73.8%	99.1%	100.0%
Steroids	75.5%	47.8%	70.0%	71.4%	43.6%	63.4%	73.8%	99.1%	100.0%
Calcineurin Inhibitor Use	92.2%	86.2%	92.1%	91.5%	92.8%	93.8%	96.0%	98.6%	100.0%
Cyclosporine	19.8%	3.6%	6.3%	7.2%	9.2%	0.9%	40.5%	16.6%	25.0%
Tacrolimus	72.4%	82.6%	85.8%	84.4%	83.6%	92.9%	55.5%	81.9%	75.0%
Antimetabolite Use	82.0%	54.3%	75.4%	79.3%	40.7%	11.6%	89.5%	82.6%	82.1%
Mycophenolate Mofetil	76.5%	47.8%	70.3%	69.8%	37.8%	7.1%	81.0%	51.0%	50.0%
Mycophenolate Sodium	3.7%	2.2%	4.1%	7.8%	0.9%	0.0%	0.9%	0.4%	0.0%
Azathioprine	1.5%	4.3%	0.3%	1.6%	2.0%	4.5%	7.5%	31.2%	32.1%
Leflunomide	0.3%	0.0%	0.6%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
mTOR Inhibitor Use	15.8%	23.2%	21.8%	21.8%	11.7%	17.9%	10.9%	7.9%	7.1%
Sirolimus	15.6%	23.2%	21.8%	21.8%	11.7%	17.9%	10.9%	7.9%	7.1%
Everolimus	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.